PT - JOURNAL ARTICLE AU - Chris von Csefalvay TI - VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines AID - 10.1101/2021.06.13.21258851 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.13.21258851 4099 - http://medrxiv.org/content/early/2021/06/15/2021.06.13.21258851.short 4100 - http://medrxiv.org/content/early/2021/06/15/2021.06.13.21258851.full AB - Neuroautoimmune disorders, such as multiple sclerosis and Guillain-Barre syndrome, have been documented in relation to various vaccines in the past. This paper uses passive reporting information from the CDC/FDA’s VAERS system to analyse whether neuroautoimmune presentations are reported at a relatively higher or lower rate, vis-a-vis other adverse effects, for COVID-19 vaccines than for other vaccines. Through computing the reporting odds ratios for a range of symptoms and comparator vaccines, a clear indication in favour of the safety of COVID-19 vaccines emerges, with reports of neuroautoimmune adverse events in relation to other adverse events being over 70% less likely for COVID-19 than for comparator vaccines (ROR : 0.292, p < 0.0001). In comparison with other vaccines given as part of routine care in adulthood, COVID-19 vaccines have the lowest reporting odds ratio of neuroautoimmune adverse effects (median ROR: 0.246).Competing Interest StatementCvC is a consultant to a company that may be affected by the research reported in this paper. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.Funding StatementThis research was funded by Starschema Inc. under its intramural research funding programme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval has been sought as the study involves publicly available data released by the CDC/FDA.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSource data can be obtained from the FDA/CDC's VAERS site. All code is publicly available on Github and under the DOI 10.5281/zenodo.4940261. https://vaers.hhs.gov/data.html https://github.com/chrisvoncsefalvay/covid19-neuroautoimmune-aefis AEFIAdverse event following immmunizationCDCCenters for Disease Control and PreventionCISclinically isolated syndromeEUAEmergency Use AuthorizationFDAFood and Drug AdministrationGBSGuillain-Barre syndromemRNAmessenger RNAMSmultiple sclerosisRISradiologically isolated syndromeRORReporting Odds RatioVAERSVaccine Adverse Effect Reporting System